Use this guide one step at a time.
Leukemia is a family of blood cancers, so the exact name matters before the treatment plan makes sense. Acute and chronic forms can differ greatly in urgency, medicines, monitoring, and whether treatment begins immediately. Blood, marrow, chromosome, gene, and measurable residual disease results help define the disease and track response.
Key points
- Get written instructions for fever, infection, bleeding, breathlessness, neurologic symptoms, and treatment complications, including whom to contact after hours.
Subtypes and biomarkers
The four broad adult categories are acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia, but each contains biologically distinct subtypes. Acute leukemias usually require rapid classification because treatment may be time-sensitive; chronic leukemias may be found before symptoms and do not always require immediate therapy. Flow cytometry identifies whether abnormal cells are myeloid or lymphoid and their surface markers. Chromosome studies, fluorescence in situ hybridization, and molecular sequencing can reveal changes that define the disease, estimate risk, or point to targeted treatment. BCR::ABL1 is central to CML and occurs in some ALL; AML and CLL use different panels of gene and chromosome findings. Measurable residual disease testing looks for leukemia below what standard microscopy can see and may help assess response or recurrence risk, although the method and timing depend on subtype. Inherited testing is considered separately when age, family history, or disease features raise concern.
What is leukemia?
Leukemia begins when a blood-forming cell acquires changes that disrupt normal growth and maturation. Abnormal cells can accumulate in marrow and blood, crowding out healthy red cells, infection-fighting white cells, and platelets. “Acute” leukemias usually progress rapidly and contain many immature cells; “chronic” leukemias often develop more slowly, although their course varies. “Lymphoblastic” or “lymphocytic” identifies lymphoid-lineage disease, while “myeloid” identifies myeloid-lineage disease. Leukemia can occur at any age, but the pattern differs by subtype: it is the most common cancer category in children, while several chronic forms occur mainly in adults. Some cases are found through routine blood testing before symptoms develop. Leukemia is not a single diagnosis, so subtype classification is essential before selecting therapy. Care depends on the leukemia type, whether it is newly diagnosed, in remission, progressive, or recurrent, relevant biomarkers, prior therapy, age, and general health.
Signs and symptoms
Possible symptoms reflect reduced normal blood-cell production or accumulation of leukemia cells. They may include persistent fatigue or weakness from anemia; fever, frequent infections, or night sweats; easy bruising, nosebleeds, bleeding gums, pinpoint red skin spots, or unusually heavy bleeding; and bone or joint discomfort. Some people develop unexplained weight loss, reduced appetite, shortness of breath, pale skin, swollen lymph nodes, or a feeling of fullness under the ribs from an enlarged spleen or liver. Acute forms can cause symptoms over days or weeks, while chronic forms may cause few symptoms and be detected on a blood count. These findings are not specific to leukemia and can result from infections, medicines, immune disorders, or other noncancer conditions. Persistent, worsening, or unexplained symptoms warrant clinical assessment rather than self-diagnosis.
Diagnosis and staging
Evaluation starts with a health history, examination, and complete blood count with differential. A peripheral blood smear can show abnormal numbers, shapes, or maturity of blood cells. Bone marrow aspiration and biopsy are often needed to confirm the diagnosis and measure abnormal cells. Flow cytometry or immunophenotyping identifies cell lineage and surface markers. Cytogenetic, fluorescence in situ hybridization, and molecular tests look for chromosome or gene changes that refine the subtype, estimate risk, and help select targeted treatment. Additional blood chemistry, infection screening, lumbar puncture, or imaging may be used according to the suspected type and symptoms. Many leukemias do not use the solid-tumor stage I–IV system. Instead, clinicians describe subtype, genetic-risk group, disease phase or status, spread to sites such as the central nervous system, and response, including measurable residual disease. The relevant framework depends on the precise leukemia and biomarkers.
Established treatment paths
Treatment differs substantially among leukemia types. Acute leukemias commonly require prompt induction therapy to achieve remission, followed by consolidation and sometimes maintenance therapy. Regimens may include multi-drug chemotherapy, targeted medicines chosen for molecular changes, immunotherapy, or stem cell transplantation in selected patients. Central nervous system–directed therapy is routine in acute lymphoblastic leukemia and may be used in other settings. Chronic lymphocytic leukemia may be observed without immediate treatment when asymptomatic; when treatment is needed, targeted oral agents and antibody-based combinations are common. Chronic myeloid leukemia is usually treated with a BCR::ABL1 tyrosine kinase inhibitor and monitored with molecular testing. Radiation has limited, situation-specific roles, such as symptom relief or transplant preparation. Relapsed or refractory disease may require a different targeted agent, immunotherapy, cellular therapy, transplant, or a clinical trial. The plan depends on type, disease phase or status, cytogenetic and molecular biomarkers, prior response, age, organ function, and patient preferences. A hematology-oncology team interprets these factors and monitors response and toxicity. Treatment is adjusted when response testing or adverse effects show that the original approach is no longer appropriate.
Supportive care
Leukemia and its treatment can sharply lower infection-fighting cells, red cells, and platelets. Get a written fever threshold and 24-hour contact plan; infection during treatment can become serious quickly. The team may also plan for tumor lysis, nausea, mouth sores, pain, fatigue, nutrition, fertility preservation, and line care. Rehabilitation, counseling, social work, and palliative care can support function and quality of life during active treatment or observation.
Profiles documenting leukemia care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
Sources
Source information checked: 2026-10-01. The links below identify the public and clinic-provided materials used for this page.
- NCI: Leukemia—Patient Version ↗Checked 2026-09-29
- NCI Dictionary: Leukemia ↗Checked 2026-09-29
- NCI: Infection and Neutropenia During Cancer Treatment ↗Checked 2026-10-01
- NCI: Bleeding and Bruising During Cancer Treatment ↗Checked 2026-10-01
- NCI: Stem Cell Transplants in Cancer Treatment ↗Checked 2026-10-01
How Cancer Clinic Finder compiles information · Suggest a factual correction
